Last reviewed · How we verify
Predetermined treatment duration
Predetermined treatment duration is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.
Predetermined treatment duration is not specified in the provided facts. However, ClinicalTrials.gov indicates that the conditions studied include Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation, Joint Instability, Chronic Disease, and Sprains, and interventions include Circumferential PV isolation, Circumferential PVI+renal denervation, and Jumping exercise.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Predetermined treatment duration |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (PHASE2)
- Radiofrequency Ablation of Adenomyosis (NA)
- PROtecting Maternal Brains From Injury and Stroke (NA)
- Trial of Family Focused Grief Therapy in Palliative Care and Bereavement (NA)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Impact of Bupivacaine Dilution With Dextrose or Saline on Infraclavicular Block Outcomes (NA)
- Effect Of Different Sodium Hypochlorite Concentrations On Intracanal Substance P, CGRP And Opiorphin Levels And Postoperative Pain During Root Canal Retreatment (NA)
- SCAN Targeted Epidural Modulation for Parkinson's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Predetermined treatment duration CI brief — competitive landscape report
- Predetermined treatment duration updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Predetermined treatment duration
What is Predetermined treatment duration?
Who makes Predetermined treatment duration?
What development phase is Predetermined treatment duration in?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing